Medicine, Hematology Oncology Division

Grants

Grants per year 1995 2007 2008 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020 2021 2028

• 468 Active
• 1104 Finished

Grants per year

Search results

• DYRK1A is a novel target in B-Cell leukemia

  Crispino, J. D.

  Rally Foundation, Inc.

  7/1/18 → 6/30/19

  Project: Research project

  • B-Cell Leukemia 100%
  • Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 55%
  • Growth Inhibitors 46%
  • Caspase 9 40%
  • Phosphotransferases 27%

• The Role of Chaf1b in malignant and normal hematopoiesis

  Crispino, J. D.

  American Society of Hematology

  7/1/17 → 6/30/19

  Project: Research project

  • Chromatin Assembly and Disassembly 100%
  • Hematopoiesis 69%
  • Chromatin 31%
  • Hematopoietic Stem Cells 28%
  • Chromatin Assembly Factor-1 25%

• Prot #D6060C00002: A Phase 1 Multicenter, Open-label, Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, Immunogenicity, and Antitumor Activity of MEDI0562 in Combination with Immune Therapeutic Agents in Adult Subjects with Advanced Solid

  Chae, Y. K. & Giles, F. J.

  ICON Clinical Research, LLC, MedImmune, LLC

  6/30/16 → 6/30/19

  Project: Research project

• Prot #20130232: A Phase 1b/3 Multicenter, Randomized, Open-label Trial of Talimogene Laherparepvec in combination with Pembrolizumab for the Treatment of Subjects With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck

  Agulnik, M.

  Amgen, Inc.

  6/23/16 → 6/23/19

  Project: Research project

• Prot #AV-951-12-204: A Phase 2 Randomized, Double-Blind, Placebo-Controlled, 2-Arm, Multi-Center Study Comparing Tivozanib Hydrochloride In Combination With Paclitaxel Versus Placebo In Combination With Paclitaxel in the Treatment of Subjects With Locally

  Gradishar, W. J.

  AVEO Pharmaceuticals, Inc.

  6/20/13 → 6/20/19

  Project: Research project

• Prot #D4190C00021: A Phase 1b/2 Study of MEDI4736 in Combination with Tremelimumab, MEDI4736 Monotherapy, and Tremelimumab Monotherapy in Subjects with Metastatic or Recurrent Gastric or Gastroesophageal Junction Adenocarcinoma

  Benson III, A. B.

  PRA Health Sciences, MedImmune, LLC

  6/16/16 → 6/16/19

  Project: Research project

• Impact of Cachexia on Clinical Outcomes in Aggressive Lymphomas

  Karmali, R.

  Lymphoma Research Foundation

  9/1/16 → 6/15/19

  Project: Research project

  • Cachexia 100%
  • Immunotherapy 64%
  • B-Cell Lymphoma 57%
  • Non-Hodgkin's Lymphoma 51%
  • Lymphoma 47%

• Prot #BAY 1436032/19036: An open-label, non-randomized, multicenter Phase I study to determine the maximum tolerated and/or recommended Phase II dose of oral mutant IDH1 (mIDH1) inhibitor BAY 1436032 and to characterize its safety, tolerability, pharmacok

  Altman, J. K.

  Covance Inc., Bayer HealthCare Pharmaceuticals, Inc.

  2/22/18 → 6/1/19

  Project: Research project

• Prot #VX12-970-001: An Open-Label, First-in-Human Study of the Safety, Tolerability, and Pharmacokinetics of VX-970 in Combination With Cytotoxic Chemotherapy in Subjects With Advanced Solid Tumors

  Gradishar, W. J.

  Quintiles, Inc., Vertex Pharmaceuticals Incorporated

  5/16/16 → 5/16/19

  Project: Research project

• Prot #006-00: A Multicenter, Randomized, Controlled, Two-Arm, Phase III Study to Evaluate the Safety and Efficacy of MK-3475 Compared to Ipilimumab in Patients with Advanced Melanoma

  Chandra, S.

  Merck Sharp & Dohme Corporation

  5/3/13 → 5/3/19

  Project: Research project

• Prot #COTI2-101: A Phase 1 Study Of COTI-2 For The Treatment Of Advanced Or Recurrent Gynecologic Malignancies

  Matei, D. E. & Chae, Y. K.

  Critical Outcome Technologies Inc.

  5/2/16 → 5/2/19

  Project: Research project

• CMIDD

  Zhao, M., Mazar, A. P., O'Halloran, T. V., Ugolkov, A. & Zhao, M.

  National Cancer Institute

  5/7/14 → 4/30/19

  Project: Research project

  • Whole Body Imaging 100%
  • technetium 99m HYNIC-duramycin 81%
  • Apoptosis 34%
  • Antineoplastic Combined Chemotherapy Protocols 32%
  • Pharmaceutical Preparations 31%

• (PQD5) imaging systemic tissue injuries induced by anticancer drugs

  Mazar, A. P., Zhao, M., Rademaker, A. W., Schiltz, G. E., Ugolkov, A., Hou, S. & Mishra, R. K.

  National Cancer Institute

  5/7/14 → 4/30/19

  Project: Research project

  • Whole Body Imaging 100%
  • technetium 99m HYNIC-duramycin 81%
  • Wounds and Injuries 42%
  • Pharmaceutical Preparations 39%
  • Apoptosis 34%

• Prot #D4190C00023: A Phase 1b Study to Evaluate the Safety and Efficacy of MEDI4736 as Monotherapy and in Combination with Tremelimumab or AZD9150 in Subjects with Relapsed or Refractory Diffuse Large B-cell Lymphoma

  Pro, B.

  ICON Clinical Research, LLC, MedImmune, LLC

  4/29/16 → 4/29/19

  Project: Research project

• Prot #B1931022: An Open-label, Randomized Phase 3 Study of Inotuzumab Ozogamicin Compared to a Defined Investigator's Choice in Adult Patients with Relapsed or Refractory CD22-Positive Acute Lymphoblastic Leukemia (ALL)

  Frankfurt, O.

  ICON Clinical Research, LLC, Pfizer Inc.

  4/24/13 → 4/24/19

  Project: Research project

• Northwestern and Jos University Research Training Program in HIV and Malignancies

  Murphy, R. L., Achenbach, C. J., Achenbach, C. J., Agulnik, M., Hou, L. & Longnecker, R. M.

  John E. Fogarty International Center for Advanced Study in the Health Sciences

  5/9/14 → 4/18/19

  Project: Research project

  • Acquired Immunodeficiency Syndrome 100%
  • HIV 69%
  • Education 51%
  • Neoplasms 43%
  • Nigeria 41%

• Prot #002-00: Randomized, Phase II Study of MK-3475 versus Chemotherapy in Patients with Advanced Melanoma

  Kuzel, T. M.

  Merck Sharp & Dohme Research Laboratories

  4/14/13 → 4/14/19

  Project: Research project

• Prot #CA180399: An Open Label, Randomized (2:1) Phase 2b Study of Dasatinib vs. Imatinib in Patients With Chronic Phase Chronic Myeloid Leukemia Who Have Not Achieved an Optimal Response to 3 Months of Therapy with 400 mg Imatinib

  Frankfurt, O.

  ICON Clinical Research, LLC, Bristol-Myers Squibb Company

  4/8/13 → 4/8/19

  Project: Research project

• Prot #D791PC00001: A Phase I, Open-Label, Multicentre Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-tumour Activity of gefitinib in Combination with MEDI4736 (anti PD-L1) in Subjects with Non-Small Cell Lung Cancer(NSCLC)

  Chae, Y. K.

  DrugDev Inc., AstraZeneca Pharmaceuticals LP

  3/31/16 → 3/31/19

  Project: Research project

• The Role of NOV (CCN3) in Prostate Cancer Progression

  Yu, J.

  National Cancer Institute

  4/1/16 → 3/31/19

  Project: Research project

• Prot #391402: A Phase 1/2a, Open-Label, Parallel, Two-Arm Dose-Escalation Study to Assess the Safety, Tolerability, Efficacy, Pharmacokinetics, and Pharmacodynamics of BAX69 in Subjects with Refractory Ovarian Cancer with Malignant Ascites

  Chae, Y. K.

  Quintiles, Inc., Baxalta US Inc.

  3/17/16 → 3/17/19

  Project: Research project

• Prot #FLX925-01: Phase 1/1b, First-in-Human, Dose-Escalation and Expansion Study of FLX925 Administered Orally to Subjects with Relapsed or Refractory Acute Myeloid Leukemia

  Dinner, S. N.

  Medpace, Inc., FLX Bio, Inc.

  3/16/16 → 3/16/19

  Project: Research project

• Prot #265-109: Phase 2, Parallel-Arm Study of MGCD265 in Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer with Activating Genetic Alterations in Mesenchymal-Epithelial Transition Factor

  Mohindra, N. A.

  Clinverse, Inc., Mirati Therapeutics Inc.

  3/14/16 → 3/14/19

  Project: Research project

• Prot #M15-330: A Phase 1b/2 Study of Duvelisib and Venetoclax in Subjects with Relapsed or Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Indolent or Aggressive Non-Hodgkin Lymphoma, Who Have Not Previously Received a Bcl-2 or PI3

  Ma, S.

  AbbVie Inc.

  3/3/16 → 3/3/19

  Project: Research project

• The role of ICSBP in the pathogenesis of chronic myeloid leukemia

  Eklund, E. A. & Huang, W.

  National Cancer Institute

  3/1/16 → 2/28/19

  Project: Research project